跳至主要内容
临床试验/NCT06595160
NCT06595160招募中不适用

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma Patients

Emory University1 个研究点 分布在 1 个国家目标入组 87 人开始时间: 2024年8月5日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
87
试验地点
1
主要终点
Fecal Microbiome Alpha Diversity

研究概览

简要总结

This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.

详细描述

PRIMARY OBJECTIVES:

I. Evaluate the association between pre-treatment diversity of the fecal microbiome and major pathological response to neoadjuvant chemotherapy in operable pancreatic ductal adenocarcinoma patients.

II. Evaluate the association between pre-treatment HEI-2015 dietary score and major pathological response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients.

III. Evaluate the association between pre-treatment HEI-2015 dietary score and diversity of the fecal microbiome in pancreatic ductal adenocarcinoma patients.

OUTLINE: This is an observational study.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • * Age ≥ 18 years with signed informed consent form
  • Patients must have a histological diagnosis of PDAC
  • Resectable or borderline resectable PDAC on imaging

排除标准

  • * Patients with locally advanced and metastatic stage IV PDAC
  • Patients who have already received or completed neoadjuvant chemotherapy for PDAC
  • Patients with active malignancy receiving systemic therapy

结局指标

主要结局

Fecal Microbiome Alpha Diversity

时间窗: Through study completion, an average of two years

Continuous variables will be presented as median with interquartile range and categorical variables will be presented as frequencies. Univariate logistic regression will be used to compare alpha diversity (mean inverse Simpson index) and relative abundance of operational taxonomic units up to species level in PDAC patients with and without major pathological response to neoadjuvant chemotherapy. Multivariable logistic regression analyses will be performed to identify significant factors associated with major pathological response after adjusting for age, gender, stage at presentation, and type of neoadjuvant chemotherapy and other factors based on univariate analyses or clinical significance.

次要结局

  • Pathological Response Rate(Through study completion, an average of two years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mihir M. Shah, MD, FACS, FSSO

Principal Investigator

Emory University

研究点 (1)

Loading locations...

相似试验